Edition:
India

Bio Path Holdings Inc (BPTH.OQ)

BPTH.OQ on NASDAQ Stock Exchange Capital Market

5.02USD
10:08pm IST
Change (% chg)

$-0.02 (-0.40%)
Prev Close
$5.04
Open
$5.12
Day's High
$5.12
Day's Low
$5.01
Volume
2,526
Avg. Vol
15,799
52-wk High
$13.33
52-wk Low
$2.94

Latest Key Developments (Source: Significant Developments)

Bio Path Holdings Q1 Loss Per Share $0.90
Friday, 15 May 2020 

Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.90.  Full Article

Bio-Path Says In 2020, Intends To Continue Its Efforts To Expand Number Of Sites, Including European-Based Sites, To Enhance Patient Enrollment
Wednesday, 8 Jan 2020 

Jan 8 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2020 BUSINESS OUTLOOK.BIO PATH HOLDINGS - IN 2020, INTENDS TO CONTINUE ITS EFFORTS TO EXPAND NUMBER OF SITES, INCLUDING EUROPEAN-BASED SITES, TO ENHANCE PATIENT ENROLLMENT..BIO PATH HOLDINGS INC - IN 2020 BIO-PATH EXPECTS TO COMPLETE SEVERAL IND-ENABLING STUDIES FOR BP1003.  Full Article

Bio-Path Announces $8 Mln Registered Direct Offering Priced At-The-Market
Thursday, 21 Nov 2019 

Nov 21 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS ANNOUNCES $8.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.BIO PATH - ENTERED AGREEMENTS WITH INVESTORS FOR SALE OF 808,080 COMMON SHARES & WARRANTS TO BUY UP TO 606,060 COMMON SHARES AT $9.90/SHARE & WARRANT.BIO PATH - WARRANTS WILL HAVE EXERCISE PRICE OF $9.90 PER SHARE AND EXERCISE PERIOD COMMENCING IMMEDIATELY UPON ISSUANCE AND A TERM OF 5 YEARS.  Full Article

Bio Path Holdings Q3 Loss Per Share $0.78
Friday, 15 Nov 2019 

Nov 15 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.78.AS OF SEPTEMBER 30, 2019, COMPANY HAD CASH OF $15.4 MILLION, COMPARED TO $1.0 MILLION AT DECEMBER 31, 2018.BIO PATH HOLDINGS- EXPECT TO FILE IND APPLICATION FOR PHASE 1 STUDY OF BP1003 FOR TREATMENT OF SOLID TUMORS INCLUDING PANCREATIC CANCER IN 2020.  Full Article

Bio-Path Holdings Reports Second Quarter 2019 Financial Results
Thursday, 15 Aug 2019 

Aug 15 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.87.AS OF JUNE 30, 2019, COMPANY HAD CASH OF $17.1 MILLION.  Full Article

Bio Path Holdings Files For Stock Shelf Of Up To $125 Mln
Friday, 17 May 2019 

May 16 (Reuters) - Bio Path Holdings Inc ::BIO PATH HOLDINGS FILES FOR STOCK SHELF OF UP TO $125 MILLION - SEC FILING.  Full Article

Bio-Path Holdings Q1 Loss Per Share $0.89
Thursday, 16 May 2019 

May 16 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.89.AS OF MARCH 31, 2019, COMPANY HAD CASH OF $19.3 MILLION, COMPARED TO $1.0 MILLION AT DECEMBER 31, 2018.  Full Article

Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering
Friday, 18 Jan 2019 

Jan 18 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS, INC. ANNOUNCES $1.7 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.ENTERED AGREEMENTS WITH INSTITUTIONAL INVESTORS FOR ISSUANCE AND SALE OF 648,302 SHARES OF COMMON STOCK AT $2.65/SHARE.  Full Article

Bio-Path Holdings Provides Clinical Update And 2019 Business Outlook
Thursday, 27 Dec 2018 

Dec 27 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS PROVIDES CLINICAL UPDATE AND 2019 BUSINESS OUTLOOK.BIO PATH HOLDINGS - EXPECTS TO INITIATE PHASE 1 CLINICAL TRIAL OF BP1002 IN REFRACTORY OR RELAPSED LYMPHOMA AND CLL PATIENTS IN 2019.BIO PATH HOLDINGS INC - IN 2019, BIO-PATH INTENDS TO INITIATE A PHASE 1 CLINICAL TRIAL OF PREXIGEBERSEN IN PATIENTS WITH ADVANCED SOLID TUMORS.  Full Article

Bio-Path Holdings reports third quarter results
Thursday, 15 Nov 2018 

Nov 15 (Reuters) - Bio Path Holdings Inc ::BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.27.AS OF SEPTEMBER 30, 2018, COMPANY HAD CASH OF $2.3 MILLION, COMPARED TO $6.0 MILLION AT DECEMBER 31, 2017.  Full Article

BRIEF-Bio Path On July 2, Delivered Written Notice To Cantor Fitzgerald That It Had Elected To Terminate Sales Agreement Effective As Of July 12, 2020

* BIO PATH - ON JULY 2,DELIVERED WRITTEN NOTICE TO CANTOR FITZGERALD THAT IT HAD ELECTED TO TERMINATE SALES AGREEMENT EFFECTIVE AS OF JULY 12, 2020